April, 2012

iSonea Announces Changes to Board of Directors

March, 2012

iSonea Launches Pediatric Asthma Study

iSonea Adds Dr. David Dantzker to Board of Directors

iSonea Looks to turn a Smartphone into a Breathing Monitor

iSonea's tech is Covered for Accoustic Monitoring

Cambride Consultants Demos Asthma Training Device

iSonea Issued US Patent for Cough Detector to Diagnose Respiratory Conditions

Dr. Lynn M. Taussig Named Chairman of iSonea’s Medical Advisory Board

February, 2012

FY2012 Half Year Report

iSonea and Qualcomm Life Collaborate on Asthma Mobile Health Technology

Proactiveinvestors News: iSonea rapidly approaches commercialisation, targets US$16 billion asthma market

CEO Shareholder Update and Q2 FY2012 Results

January, 2012

New Viriathus Healthcare Report Covers iSonea, January, 2012

iSonea to present at Cappello Capital Corp Investor Conference

New Issue Announcement,
Application for Quotation of Additional Securities and Agreement

iSonea Limited Commences Trading on the U.S. OTCQX International

iSonea Limited Announces Publication of Initial Viriathus Research Report



Management Team

Michael J. Thomas - Chief Executive Officer

Mr. Thomas became the new CEO of iSonea Ltd in June 2011. He has over 22 years of healthcare industry experience. He is the President and CEO of Appian Partners, a medical devices and healthcare services consulting firm. Earlier in his career, Thomas was President and CEO of Sleep Solutions, a VC-backed medical device manufacturer.  He helped to raise over $50 million in VC funding for that company and launch a new industry in the $5B Sleep Medicine market. Thomas successfully lobbied the largest Managed Care Organizations (MCOs) and the Centers for Medicare and Medicaid Services (CMS) to alter their medical policy and approve reimbursement for in-home sleep apnea diagnostic services.  Prior to joining Sleep Solutions, Thomas wasEVP of Sales and Marketing for National Sleep Technologies (NST), where he led acquisitions of more than 80 sleep labs, making NST the largest sleep-testing company in the US. NST was later sold to GE Medical. Earlier in his career, Thomas was Vice President of Sales at Patient InfoSystems (NASDAQ: PATI) and instrumental in taking that company public. He began his career in sales and marketing at Merck and GlaxoWellcome. Thomas graduated from Cornell University with a degree in Microbiology.

Stephen Tunnell, RRT – Senior Vice President of Operations:

Mr. Tunnell has more than 32 years of healthcare industry experience and is extremely knowledgeable about respiratory disorders. He began his career as a registered respiratory therapist. During the 1980s, Tunnell served as Technical Director of Pulmonary Services at Sharp Healthcare in California. He joined Mallinckrodt during the 1990s, where he served as General Manager of Nellcor Puritan Bennett’s Ventilator Systems division. In 2000 he co-founded and led eVent Medical, a life support business.

David Model – Senior Vice President of Finance:

Mr. Model has 32 years of business experience in biotech, biomedical, aerospace and other high technology fields. He has been a C level executive for a variety of both public and private companies, most recently as the CFO of AduroBioTech, an immunotherapy company, and an Executive Vice President for Triton Systems, a product venturing company.  Earlier in his career Mr. Model was a founder and President of ImageMax (now DataBank IMX), a nationwide network of data imaging businesses.  The company had an IPO on the NASDAQ in 1997. Prior to that, Mr. Model founded and co-managed Airfoil Technologies, LLC, a joint venture between Teleflex (TFX: NYSE) and General Electric Aviation to provide the world's commercial airlines with turbine repair services, a venture which General Electric acquired in 2009.

Jonathan Freudman, MD – Medical Director:

Dr.Freudman has 25 years of healthcare experience, including 16 years practicing internal medicine for Kaiser Permanente, during which time he helped establish disease management programs for asthma, diabetes, and heart failure. He was in charge of technology assessment at Blue Shield of California, and has been an industry consultant since 2002 assisting early-stage healthcare companies with clinical trial design and aspects of new product commercialization. His clients have included VC-backed medical device companies and biotech companies.   Dr. Freudman’s specializes in reimbursement strategies and he will play a key role over the next 12 months in helping the Company secure Category I CPT code reimbursement.  He is also on faculty at the University of California San Francisco School of Medicine.

Michael A. Cheney – Vice President of Marketing: 

Mr. Cheney has 25 years of experience as a strategic marketing leader for pharmaceutical, biotechnology, and medical device companies.  He has launched major market-shaping brands for Wyeth Laboratories and BASF/Knoll Pharmaceuticals.  For 6 years, he was VP Marketing and responsible for the International Business Unit at Cyberonics, Inc., a pioneer in neurostimulation therapy devices for CNS disorders.  He also has experience in the respiratory care/sleep disordered breathing market (NovaSom Inc.), where he developed marketing strategies to increase adoption of home sleep tests for the diagnosis of sleep apnea.

Jan P. Barker  - Vice President of Business Development: 

Ms. Barker brings experience in venture capital investing and fund raising, board of director participation, company growth and exits, leadership, management and a broad coalition of business skills from her 25 year career in healthcare.  Ms. Barker was a partner with MedVenture Associates, a venture fund investing in healthcare for 6 years.  Prior to that she was a founder and managing member of The Crucible Group, LLC, a venture development organization.  In both partnerships she participated in private equity related investments in the device, systems and information technology segments of healthcare. Her capabilities include sourcing deals, analyzing potential, and assisting entrepreneurial ventures in obtaining seed and additional capital rounds, business plan development, strategic planning insight, operations assistance, recruitment of key personnel and Board of Director participation.  She has a broad combination of complementary skills in the healthcare entrepreneurial environment. Her diverse experience has included ‘C’ level management in multiple organizations.

Mr. Paul Eisen - Executive Director, Sales & Marketing for Europe, Asia Pacific & Australia

Paul Eisen has operated as a senior executive in the Medical device and Healthcare industry across Australia and Asia Pacific for the last 20 years. Paul holds a degree in Diagnostic Radiography from Sydney Technical Institute and a Graduate Diploma in Marketing from the University of Technology, Sydney (UTS).


© 2012 iSonea (formerly Karmelsonix) Ltd| Disclaimer, Terms and Conditions, Copyright and Intellectual Property.

BlackFin Processor
BlackFin® Processor
KarmelSonix ISO Certification
ISO Certification 2003
US Food & Drug Administration

US Food & Drug Administration
Australian Government

Australian Government
Therapeutic Goods Administration

CE Certification

CE Certification